Tapur Targeted Agent And Profiling Utilization Registry (Tapur) Study
Posted Date: Jul 19, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The primary objective of this study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. This study will consist of multiple arms and efficacy will be measured by objective response rate, which will be defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria.
Histologically-Proven Locally Advanced Or Metastatic Solid Tumor, Multiple Myeloma Or B Cell Non-Hodgkin Lymphoma Who Is No Longer Benefiting From Standard Anti-Cancer Treatment Or For Whom, In The Opinion Of The Treating Physician, No Such Treatment Is Available Or Indicated. Ecog Score Of 0-2. Absolute Neutrophil Count = 1.5 X 106/µl. Hemoglobin > 9.0 G/Dl. Platelets > 75,000/µl. Total Bilirubin < 2.0 Mg/ Dl, Except In Patients With Gilbert's Syndrome. Serum Creatinine = 1.5 × Uln Or Calculated Or Measured Creatinine Clearance = 50 Ml/Min/1.73 M2. No Patients Whose Disease Is Not Measurable Or Cannot Be Assessed By Radiographic Imaging Or Physical Examination. No Patients With Primary Brain Tumors Or Leptomeningeal Metastases.
Lymphoma, Myeloma, Tumors
For More Information:
Uc Cancer Center